文献速递心脑血管急症

急性冠脉综合征患者低剂量普拉格雷与标准剂量氯吡格雷治疗的缺血与出血事件比较

Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
PubMed 文献 · JAMA Netw Open · 2020-04-01
一句话结论日本急性冠脉综合征PCI患者中,低剂量普拉格雷与氯吡格雷缺血事件相当,但出血事件显著增高(OR 2.91),尤其在高出血风险、女性、STEMI或CKD患者中。

该研究基于日本心血管数据库-庆应院际心血管研究注册,纳入2770例2014至2018年接受PCI并服用低剂量普拉格雷(负荷20 mg,维持3.75 mg)或氯吡格雷(负荷300 mg,维持75 mg)联合阿司匹林的急性冠脉综合征患者,进行倾向评分匹配分析。匹配后低剂量普拉格雷组与氯吡格雷组主要缺血事件无显著差异(OR 1.42,95%CI 0.90-2.23),但主要出血事件显著增高(OR 2.91,95%CI 1.63-5.18)。出血增高与高出血风险特征(≥75岁、体重<60 kg、卒中或TIA史)、女性、STEMI或CKD相关。作者认为,即使使用较低批准剂量,选择P2Y12抑制剂前也应评估出血风险。

要点

  • 匹配后低剂量普拉格雷组主要缺血事件与氯吡格雷组无显著差异(OR 1.42,95%CI 0.90-2.23)。
  • 匹配后低剂量普拉格雷组主要出血事件显著高于氯吡格雷组(OR 2.91,95%CI 1.63-5.18)。
  • 高出血风险特征(≥75岁、体重<60 kg、卒中或TIA史)者低剂量普拉格雷出血OR 4.08(95%CI 1.86-8.97)。
  • 女性(OR 3.84,95%CI 1.05-14.0)、STEMI(OR 2.07,95%CI 1.05-4.09)、CKD(OR 4.78,95%CI 1.95-11.7)与低剂量普拉格雷出血增高相关。
  • 作者认为,选择P2Y12抑制剂前应评估出血风险,即使使用较低批准剂量。

适用人群与场景

  • 日本接受PCI并服用低剂量普拉格雷(负荷20 mg,维持3.75 mg)或氯吡格雷(负荷300 mg,维持75 mg)联合阿司匹林的急性冠脉综合征患者,年龄均值67.8岁(SD 12.7),男性78.2%。

处置流程与药物剂量

  • 低剂量普拉格雷:负荷剂量20 mg,维持剂量3.75 mg,联合阿司匹林,用于接受PCI的急性冠脉综合征患者。
  • 氯吡格雷:负荷剂量300 mg,维持剂量75 mg,联合阿司匹林,用于接受PCI的急性冠脉综合征患者。

研究设计与关键结果

  • 研究类型:多中心回顾性队列研究,基于日本心血管数据库-庆应院际心血管研究注册,纳入2770例患者,其中2559例纳入分析;1297例(50.7%)接受低剂量普拉格雷,1262例(49.3%)接受氯吡格雷。
  • 倾向评分匹配后,低剂量普拉格雷组与氯吡格雷组主要缺血事件(院内死亡、再发心肌梗死、缺血性卒中)无显著差异(OR 1.42,95%CI 0.90-2.23)。
  • 倾向评分匹配后,低剂量普拉格雷组主要出血事件(PCI后72小时内符合美国国家心血管数据注册CathPCI注册定义的出血并发症)显著高于氯吡格雷组(OR 2.91,95%CI 1.63-5.18)。
  • 高出血风险特征(≥75岁、体重<60 kg、或卒中/短暂性脑缺血发作史)者低剂量普拉格雷出血OR 4.08(95%CI 1.86-8.97);女性OR 3.84(95%CI 1.05-14.0);STEMI OR 2.07(95%CI 1.05-4.09);CKD OR 4.78(95%CI 1.95-11.7)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于接受PCI的急性冠脉综合征患者,低剂量普拉格雷与氯吡格雷缺血事件无显著差异,但出血事件显著增高,选择P2Y12抑制剂前应评估出血风险(作者认为)。
  • 高出血风险特征(≥75岁、体重<60 kg、卒中或TIA史)、女性、STEMI或CKD患者使用低剂量普拉格雷时出血风险更高。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Prasugrel was approved at a lower dose in 2014 in Japan than in the West because East Asian patients are considered more susceptible to bleeding than Western patients. However, real-world outcomes with low-dose prasugrel treatment remain unclear.

OBJECTIVE: To investigate the association of low-dose prasugrel vs standard-dose clopidogrel administration with short-term outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI).

DESIGN, SETTING, AND PARTICIPANTS: This study used data from the Japan Cardiovascular Database-Keio Interhospital Cardiovascular Studies registry, a large, ongoing, multicenter, retrospective cohort of consecutive patients who underwent PCI. The present cohort study evaluated 2770 patients with acute coronary syndrome who underwent PCI and received either low-dose prasugrel (loading dose, 20 mg; maintenance dose, 3.75 mg) or clopidogrel (loading dose, 300 mg; maintenance dose, 75 mg) in combination with aspirin between 2014 and 2018. Propensity score-matching analysis was conducted to balance the baseline characteristics of patients receiving low-dose prasugrel and those receiving clopidogrel. Data analysis was conducted in June 2019.

EXPOSURES: Prescription of either low-dose prasugrel or standard-dose clopidogrel prior to PCI.

MAIN OUTCOMES AND MEASURES: Primary ischemic events (in-hospital death, recurrent myocardial infarction, and ischemic stroke) and primary bleeding events, defined as bleeding complications within 72 hours after PCI consistent with the National Cardiovascular Data Registry CathPCI Registry definition.

RESULTS: Of 2559 patients included in the study, the mean (SD) age was 67.8 (12.7) years, and 78.2% were male. In total, 1297 patients (50.7%) received low-dose prasugrel, and 1262 patients (49.3%) received clopidogrel. After propensity score matching, primary ischemic events among patients receiving low-dose prasugrel and those receiving clopidogrel were comparable (odds ratio [OR], 1.42; 95% CI, 0.90-2.23), but primary bleeding events were significantly higher among patients receiving prasugrel (OR, 2.91; 95% CI, 1.63-5.18). This increase in bleeding events was associated with the presence of a profile of high-bleeding risk (≥75 years of age, body weight <60 kg, or history of stroke or transient ischemic attack) (OR, 4.08; 95% CI, 1.86-8.97), being female (OR, 3.84; 95% CI, 1.05-14.0), or the presence of ST-segment elevation myocardial infarction (OR, 2.07; 95% CI, 1.05-4.09) or chronic kidney disease (OR, 4.78; 95% CI, 1.95-11.7).

CONCLUSIONS AND RELEVANCE: Since its approval, low-dose prasugrel has been used by nearly 80% of patients who undergo PCI. Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups. These results suggest the importance of a risk assessment of bleeding prior to selecting a P2Y12 inhibitor, even for the use of a lower approved dose, when treating patients of East Asian descent.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Shoji S, Sawano M, Sandhu AT, et al. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. JAMA Netw Open. 2020. PMID: 32239221. doi:10.1001/jamanetworkopen.2020.2004

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。